SageView Advisory Group LLC Sells 2,692 Shares of Danaher Co. (NYSE:DHR)

SageView Advisory Group LLC reduced its holdings in Danaher Co. (NYSE:DHR) by 46.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,112 shares of the conglomerate’s stock after selling 2,692 shares during the quarter. SageView Advisory Group LLC’s holdings in Danaher were worth $762,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in DHR. Norges Bank bought a new position in shares of Danaher during the 4th quarter valued at about $1,752,382,000. Wellington Management Group LLP increased its position in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the last quarter. Allen Investment Management LLC increased its position in shares of Danaher by 1,440.7% during the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after purchasing an additional 1,028,976 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Danaher during the 3rd quarter valued at about $178,850,000. Finally, Alecta Tjanstepension Omsesidigt bought a new position in shares of Danaher during the 4th quarter valued at about $161,994,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $262.78 on Monday. The stock has a market cap of $194.64 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.02 and a beta of 0.83. The firm’s 50-day moving average is $249.96 and its 200 day moving average is $239.25. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $268.98. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the business earned $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. Sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock worth $37,536,717 in the last quarter. Company insiders own 10.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DHR shares. Royal Bank of Canada raised their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. TD Cowen raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their price objective for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $267.31.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.